Aromatase inhibitors are widely used for treating metastatic male breast cancer patients but, in this setting, their use is not substantiated by prospective clinical trials, rather driven by supposed similarities existing with breast cancer in postmenopausal women [21]. Here, CYP19A1 is linked to breast carcinoma.